# Bernstein Moves Alnylam to Market Perform Over Nucresiran Trial Concerns

By Enna Lee

Canonical URL: https://www.tokenpost.com/news/investing/44904
Published: 2026-10-30T16:42:38.000Z
Updated: 2026-10-30T16:42:38.000Z
Section: Investing

> The change concerns TRITON-CM, a Phase 3 trial of nucresiran, Alnylam's next-generation RNAi therapeutic.

Bernstein shifted its rating on Alnylam Pharmaceuticals on Friday, Oct. 30, from Outperform to Market Perform, citing concerns about the design of TRITON-CM, a Phase 3 study of nucresiran.

Analyst Jeffrey Walch was behind the rating action. Nucresiran is Alnylam's next-generation RNAi therapeutic.